Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
PRProQR Therapeutics N.V. logo

ProQR Therapeutics N.V. (PRQR)

NASDAQ Global Market · Currency in USD
$1.29 ▼ -0.04 (-3.01%)
At close: Oct 23, 4:00 PM ET. Market closed.
$1.28 ▼ -0.01 (-0.78%)
After hours: Oct 23, 7:49 PM ET

Summary

Previous Close
$1.33
Open
$1.33
Day's Range
$1.24 – $1.33
52 Week Range
$1.24 – $3.00
Volume
1,785,935
Avg. Volume
1,032,714
Market Cap
$182.04M
Beta (5Y Monthly)
0.03
PE Ratio (TTM)
--
EPS (TTM)
-$0.39
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$3.00

Profile: ProQR Therapeutics N.V.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
166
CEO
Daniel Anton de Boer
Website
proqr.com

ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$0.11 · Revenue est. $4.30M
DateEst.Actual
Aug 13, 2026-$0.13-$0.10Beat
May 12, 2026-$0.15-$0.15Beat
Mar 12, 2026-$0.08-$0.09Miss
Nov 6, 2025-$0.10-$0.12Miss
Aug 7, 2025-$0.08-$0.14Miss
May 8, 2025-$0.09-$0.11Miss

Analyst view

Consensus price target
$3.00 ▲ +132.6%
Range $3.00 – $3.00
Rating: Buy
Buy 92% · Hold 8% · Sell 0%

Get free alerts on PRQR and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.